BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Homozygous Familial Hypercholesterolemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Homozygous Familial H
 ypercholesterolemia\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07037771-1192@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Zodasiran: Phase 3 readout est. (NCT07037771)
DESCRIPTION:Zodasiran\, phase 3\, Homozygous Familial Hypercholesterolemia.
 \nStudy: A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects Wit
 h Homozygous Familial Hypercholesterolemia (YOSEMITE)\nEstimated primary c
 ompletion: 20 August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zodasiran#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07037771
URL:https://assetmemo.bio/drug/zodasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597006-1034@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597006)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Safety\, Tolerability and Efficacy of I
 nclisiran in Children With Homozygous Familial Hypercholesterolemia\nEstim
 ated primary completion: 21 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06597006
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07473843-1192@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Zodasiran: Phase 3 readout est. (NCT07473843)
DESCRIPTION:Zodasiran\, phase 3\, Homozygous Familial Hypercholesterolemia.
 \nStudy: Study of Zodasiran in Adolescent Participants With Homozygous Fam
 ilial Hypercholesterolemia\nEstimated primary completion: July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zodasiran#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07473843
URL:https://assetmemo.bio/drug/zodasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05682378-1034@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20320325
DTEND;VALUE=DATE:20320326
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05682378)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Long-term Safety and Tolerability of Inclisiran in Partic
 ipants With HeFH or HoFH Who Have Completed the Pediatric ORION-16\, ORION
 -13\, ORION-20\, or ORION-19 Studies\nEstimated primary completion: 25 Mar
 ch 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisiran#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05682
 378
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
